<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01656356</url>
  </required_header>
  <id_info>
    <org_study_id>GPO AVIAN FLU Vaccine-V02</org_study_id>
    <nct_id>NCT01656356</nct_id>
  </id_info>
  <brief_title>Phase I Safety and Immunogenicity of Live Attenuated Influenza H5 Candidate Vaccine Strain A/17/Turkey/Turkey/05/133 (H5N2) in Healthy Thai Volunteers</brief_title>
  <official_title>Phase I Safety and Immunogenicity of Live Attenuated Influenza H5 Candidate Vaccine Strain A/17/Turkey/Turkey/05/133 (H5N2) in Healthy Thai Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mahidol University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mahidol University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate safety and reactogenicity of live attenuated&#xD;
      influenza H5 vaccine candidate strain A/17/turkey/Turkey/05/133 (H5N2) manufactured by GPO,&#xD;
      in Thailand to previously healthy Thais.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      It is a phase I randomized placebo controlled trial (vaccine and placebo ratio of 2:1). A&#xD;
      phase II study is planned to be conducted following review of results of this phase.&#xD;
&#xD;
      Phase I: It is a double blind randomized placebo controlled trial involving 24 participants&#xD;
      age 18-49 years (16 will receive vaccines and 8 will receive placebo). All will be admitted&#xD;
      in the isolation ward for 10-14 days after each immunization mainly for safety assessment.&#xD;
      Two doses of live attenuated influenza H5 vaccine candidate strain A/17/turkey/Turkey/05/133&#xD;
      (H5N2) will be given by intranasal route 21 days apart. Each group of 4 participants will be&#xD;
      immunized at a time at 30-60 mins interval. All participants will be followed 21 days after&#xD;
      each immunization. Total follow up is 60 day.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2012</start_date>
  <primary_completion_date type="Actual">August 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <number_of_arms>2</number_of_arms>
  <condition>Preventive Avian Flu</condition>
  <arm_group>
    <arm_group_label>A/17/turkey/Turkey/05/133 (H5N2)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Avian Flu Vaccine</intervention_name>
    <arm_group_label>A/17/turkey/Turkey/05/133 (H5N2)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy&#xD;
&#xD;
          -  Age 18-49 years old&#xD;
&#xD;
          -  Having Thai ID card or equivalent&#xD;
&#xD;
          -  Are seronegative to the specific H5 influenza virus determined by antibody titer less&#xD;
             than 1:40 by HAI test to the corresponding antigen.&#xD;
&#xD;
          -  Anti HIV - Negative&#xD;
&#xD;
          -  All hematology &amp; biochemistry and urine analysis are within normal range or of no&#xD;
             clinical significance (not more than 1.5 times of normal value)&#xD;
&#xD;
          -  Able to read and write and sign written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known history of egg allergy&#xD;
&#xD;
          -  Having had recently influenza infection confirmed as H5&#xD;
&#xD;
          -  History of bronchial asthma&#xD;
&#xD;
          -  History of chronic lung diseases&#xD;
&#xD;
          -  History of chronic rhinitis&#xD;
&#xD;
          -  History of immunodeficiency state&#xD;
&#xD;
          -  History of immunosuppression&#xD;
&#xD;
          -  History of heavy smoking (more than 5 rolls per day)&#xD;
&#xD;
          -  History of alcoholic (pure drink 200 ml per day)&#xD;
&#xD;
          -  Acute infectious and noninfectious diseases (within 2 weeks)&#xD;
&#xD;
          -  Exacerbation of chronic diseases or cancer or HIV positives&#xD;
&#xD;
          -  Anamnestic leukocytosis, hepatitis B and C positives&#xD;
&#xD;
          -  The volunteers who have been taking immunoglobulin products or have had a blood&#xD;
             transfusion during past three months before the beginning of the experiment&#xD;
&#xD;
          -  Participation in other research study or stop participant less than 1 month&#xD;
&#xD;
          -  Pregnancy or plan to become pregnant for 60 days after enrollment or breast feeding&#xD;
&#xD;
          -  Any concomitant medication with Aspirin&#xD;
&#xD;
          -  The volunteers who have family members with immunodeficiency&#xD;
&#xD;
          -  Poultry workers&#xD;
&#xD;
          -  Have undertaken international travel within the one week prior to immunization&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>49 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Faculty of Tropical Medicine</name>
      <address>
        <city>Bangkok</city>
        <zip>10400</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <verification_date>August 2012</verification_date>
  <study_first_submitted>July 25, 2012</study_first_submitted>
  <study_first_submitted_qc>August 2, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 3, 2012</study_first_posted>
  <last_update_submitted>August 7, 2012</last_update_submitted>
  <last_update_submitted_qc>August 7, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 8, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mahidol University</investigator_affiliation>
    <investigator_full_name>Punnee Pitisuttithum</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Avian Flu</keyword>
  <keyword>H5N2</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza in Birds</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

